Design of a peptide-based vaccine against human respiratory syncytial virus using a reverse vaccinology approach: evaluation of immunogenicity, antigenicity, allergenicity, and toxicity

BackgroundAttempts to develop an hRSV vaccine have faced safety and efficacy challenges, with only three FDA-approved vaccines (Moderna’s Mresvia, Pfizer’s Abrysvo, and GSK’s Arexvy) available. These vaccines are limited to individuals over 60 years, require boosters, and only reduce disease severit...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Hadeel Alnajran, Maaweya Awadalla, Fahad M. Aldakheel, Intikhab Alam, Afaque A. Momin, Wael Alturaiki, Bandar Alosaimi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2025-03-01
Serie:	Frontiers in Immunology
Soggetti:	human respiratory syncytial virus hRSV immunoinformatics CTL epitope HTL epitope B-cell epitope
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1546254/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!